{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T22:47:51Z","timestamp":1783205271919,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s10067-024-07019-x","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T21:01:27Z","timestamp":1717448487000},"page":"2245-2252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness of generic tofacitinib in idiopathic inflammatory myositis (IIM)\u2014a retrospective analysis from Indian Myositis Registry (MyoIN)"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5271-0766","authenticated-orcid":false,"given":"Vineeta","family":"Shobha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RamyaSri","family":"Kodali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv N.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banwari","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchika","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Ganapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Dhote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Janardana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Rajasekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramnath","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"7019_CR1","doi-asserted-by":"publisher","unstructured":"Natour AEH, Kivity S (2023) Biological therapies in inflammatory myopathies. Rambam Maimonides Med J\u00a014(2):e0008. https:\/\/doi.org\/10.5041\/RMMJ.10495","DOI":"10.5041\/RMMJ.10495"},{"key":"7019_CR2","doi-asserted-by":"publisher","unstructured":"Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert V, Galloway J, Gordon P, Gregory WJ, Gunawardena H, Hanna MG, Isenberg D, Jackman J, Kiely PDW, Livermore P, Machado PM, Maillard S, McHugh N, Murphy R, Pilkington C, \u2026 British Society for Rheumatology Standards, Audit and Guidelines Working Group (2022)\u00a0British society for rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology\u00a0(Oxford, England) 61(5):1760\u20131768. https:\/\/doi.org\/10.1093\/rheumatology\/keac115","DOI":"10.1093\/rheumatology\/keac115"},{"issue":"5","key":"7019_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","volume":"14","author":"CV Oddis","year":"2018","unstructured":"Oddis CV, Aggarwal R (2018) Treatment in myositis. Nat Rev Rheumatol 14(5):279\u2013289. https:\/\/doi.org\/10.1038\/nrrheum.2018.42","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"7019_CR4","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/art.41762","volume":"73","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE (2021) Expert perspective: management of refractory inflammatory myopathy. Arthritis Rheumatol 73(8):1394\u20131407. https:\/\/doi.org\/10.1002\/art.41762","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"7019_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/acr.20015","volume":"62","author":"A Ravelli","year":"2010","unstructured":"Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C et al (2010) Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res 62(1):63\u201372. https:\/\/doi.org\/10.1002\/acr.20015","journal-title":"Arthritis Care Res"},{"issue":"1","key":"7019_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s42358-018-0030-z","volume":"58","author":"FHC de Souza","year":"2018","unstructured":"de Souza FHC, Miossi R, de Moraes JCB, Bonf\u00e1 E, Shinjo SK (2018) Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies. Adv Rheumatol 58(1):31. https:\/\/doi.org\/10.1186\/s42358-018-0030-z","journal-title":"Adv Rheumatol"},{"issue":"1","key":"7019_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1056\/NEJMc2214285","volume":"88","author":"VP Werth","year":"2023","unstructured":"Werth VP, Fiorentino DF, Vleugels RA (2023) Trial of intravenous immune globulin in dermatomyositis. N Engl J Med 88(1):94. https:\/\/doi.org\/10.1056\/NEJMc2214285","journal-title":"N Engl J Med"},{"issue":"3","key":"7019_CR8","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/rheumatology\/keac438","volume":"62","author":"R Janardana","year":"2023","unstructured":"Janardana R, Amin SN, Rajasekhar L, Pinto B, Kodishala C, Selvam S et al (2023) Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies. Rheumatology 62(3):1243\u20131247. https:\/\/doi.org\/10.1093\/rheumatology\/keac438","journal-title":"Rheumatology"},{"issue":"3","key":"7019_CR9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/art.38270","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM et al (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66(3):740\u2013749. https:\/\/doi.org\/10.1002\/art.38270","journal-title":"Arthritis Rheumatol"},{"issue":"21","key":"7019_CR10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1212\/WNL.0000000000200679","volume":"98","author":"I Pinal-Fernandez","year":"2022","unstructured":"Pinal-Fernandez I, Greenberg SA (2022) Type I interferons in dermatomyositis myoblasts: toxic effect and a potential autocrine loop. Neurology 98(21):869\u2013870. https:\/\/doi.org\/10.1212\/WNL.0000000000200679","journal-title":"Neurology"},{"issue":"6","key":"7019_CR11","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jid.2019.10.020","volume":"140","author":"C Cassius","year":"2020","unstructured":"Cassius C, Amode R, Delord M, Battistella M, Poirot J, How-Kit A et al (2020) MDA5+ dermatomyositis is associated with stronger skin type I interferon transcriptomic signature with upregulation of IFN-\u03ba Transcript. J Invest Dermatol 140(6):1276-1279.e7. https:\/\/doi.org\/10.1016\/j.jid.2019.10.020","journal-title":"J Invest Dermatol"},{"issue":"3","key":"7019_CR12","doi-asserted-by":"publisher","first-page":"e14939","DOI":"10.1111\/dth.14939","volume":"34","author":"A Paudyal","year":"2021","unstructured":"Paudyal A, Zheng M, Lyu L, Thapa C, Gong S, Yang Y et al (2021) JAK-inhibitors for dermatomyositis: a concise literature review. Dermatol Ther 34(3):e14939. https:\/\/doi.org\/10.1111\/dth.14939","journal-title":"Dermatol Ther"},{"issue":"6","key":"7019_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","volume":"58","author":"S Moghadam-Kia","year":"2019","unstructured":"Moghadam-Kia S, Charlton D, Aggarwal R, Oddis CV (2019) Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology 58(6):1011\u20131015. https:\/\/doi.org\/10.1093\/rheumatology\/key366","journal-title":"Rheumatology"},{"issue":"12","key":"7019_CR14","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1093\/rheumatology\/keab116","volume":"60","author":"T Le Voyer","year":"2021","unstructured":"Le Voyer T, Gitiaux C, Authier F-J, Bodemer C, Melki I, Quartier P et al (2021) JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology 60(12):5801\u20135808. https:\/\/doi.org\/10.1093\/rheumatology\/keab116","journal-title":"Rheumatology"},{"issue":"26","key":"7019_CR15","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1056\/NEJMc1412997","volume":"371","author":"T Hornung","year":"2014","unstructured":"Hornung T, Janzen V, Heidgen F-J, Wolf D, Bieber T, Wenzel J (2014) Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med 371(26):2537\u20132538. https:\/\/doi.org\/10.1056\/NEJMc1412997","journal-title":"N Engl J Med"},{"issue":"3","key":"7019_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2020-218690","volume":"80","author":"H Kim","year":"2021","unstructured":"Kim H, Dill S, O\u2019Brien M, Vian L, Li X, Manukyan M et al (2021) Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis 80(3):406\u2013408. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218690","journal-title":"Ann Rheum Dis"},{"key":"7019_CR17","doi-asserted-by":"publisher","first-page":"962585","DOI":"10.3389\/fped.2022.962585","volume":"10","author":"Z Wang","year":"2022","unstructured":"Wang Z, Zheng Q, Xuan W, Xu X, Lu M, Wu J et al (2022) Short-term effectiveness of baricitinib in children with refractory and\/or severe juvenile dermatomyositis. Front Pediatr 10:962585. https:\/\/doi.org\/10.3389\/fped.2022.962585","journal-title":"Front Pediatr"},{"key":"7019_CR18","doi-asserted-by":"publisher","unstructured":"Beckett M, Dutz J, Huang K (2024) Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients. RMD Open\u00a010(1):e003837. https:\/\/doi.org\/10.1136\/rmdopen-2023-003837","DOI":"10.1136\/rmdopen-2023-003837"},{"issue":"6","key":"7019_CR19","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3760\/cma.j.cn112140-20221128-01009","volume":"61","author":"QF Zhou","year":"2023","unstructured":"Zhou QF, Luo Y, He TY, Ling JY, Xu YB, Yang J et al (2023) Analysis of the clinical characteristics and therapeutic effect of refractory juvenile dermatomyositis to tofacitinib. Zhonghua Er Ke Za Zhi 61(6):538\u2013542. https:\/\/doi.org\/10.3760\/cma.j.cn112140-20221128-01009","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"2","key":"7019_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.55563\/clinexprheumatol\/hxin6o","volume":"41","author":"JJ Paik","year":"2023","unstructured":"Paik JJ, Lubin G, Gromatzky A, Mudd PN Jr, Ponda MP, Christopher-Stine L (2023) Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review. Clin Exp Rheumatol 41(2):348\u201358. https:\/\/doi.org\/10.55563\/clinexprheumatol\/hxin6o","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"7019_CR21","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/art.41602","volume":"73","author":"JJ Paik","year":"2021","unstructured":"Paik JJ, Casciola-Rosen L, Shin JY, Albayda J, Tiniakou E, Leung DG et al (2021) Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. Arthritis Rheumatol 73(5):858\u2013865. https:\/\/doi.org\/10.1002\/art.41602","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"7019_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/art.41944","volume":"74","author":"JJ Paik","year":"2022","unstructured":"Paik JJ, Shneyderman M, Gutierrez-Alamillo L, Albayda J, Tiniakou E, Perin J et al (2022) Long-term extension study of tofacitinib in refractory dermatomyositis. Arthritis Rheumatol 74(2):371\u2013372. https:\/\/doi.org\/10.1002\/art.41944","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"7019_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4103\/injr.injr_40_19","volume":"14","author":"L Gupta","year":"2019","unstructured":"Gupta L, Appani SK, Janardana R, Muhammed H, Lawrence A, Amin S, Shobha V, Rajasekhar L, Misra R (2019) Meeting report: MyoIN-Pan-India collaborative network for myositis research. Indian Journal of Rheumatology 14(2):136\u2013142. https:\/\/doi.org\/10.4103\/injr.injr_40_19","journal-title":"Indian Journal of Rheumatology"},{"key":"7019_CR24","doi-asserted-by":"publisher","unstructured":"Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, Feldman BM, Giannini EH, Miller FW, International Myositis Assessment and Clinical Studies Group (2005) International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52(9):2607\u20132615. https:\/\/doi.org\/10.1002\/art.21291","DOI":"10.1002\/art.21291"},{"issue":"4","key":"7019_CR25","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jaad.2022.10.055","volume":"88","author":"O Landon-Cardinal","year":"2023","unstructured":"Landon-Cardinal O, Guillaume-Jugnot P, Toquet S, Sbeih N, Rigolet A, Champtiaux N et al (2023) JAK inhibitors for the treatment of adult dermatomyositis: a pilot study. J Am Acad Dermatol 88(4):924\u2013926. https:\/\/doi.org\/10.1016\/j.jaad.2022.10.055","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"7019_CR26","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/keac399","volume":"62","author":"B Huang","year":"2023","unstructured":"Huang B, Wang X, Niu Y, Ding Y, Wang X, Tan Q et al (2023) Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis. Rheumatology 62(3):1227\u20131237. https:\/\/doi.org\/10.1093\/rheumatology\/keac399","journal-title":"Rheumatology"},{"issue":"2","key":"7019_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jaad.2021.07.003","volume":"86","author":"MS Min","year":"2022","unstructured":"Min MS, Alsarheed A, Kassamali B, Mazori DR, Schaefer M, Merola JF et al (2022) Tofacitinib as treatment for refractory dermatomyositis: a retrospective study from 2 academic medical centers. J Am Acad Dermatol 86(2):423\u2013425. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.003","journal-title":"J Am Acad Dermatol"},{"key":"7019_CR28","doi-asserted-by":"publisher","unstructured":"Ma C, Liu M, Cheng Y, Wang X, Zhao Y, Wang K, Wang W (2024) Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis\/dermatomyositis: a single-arm systemic meta-analysis. Front Immunol 15:1382728. https:\/\/doi.org\/10.3389\/fimmu.2024.1382728","DOI":"10.3389\/fimmu.2024.1382728"},{"key":"7019_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead404","author":"M Beckett","year":"2023","unstructured":"Beckett M, Tan J, Bonnardeaux E, Dutz J, Shojania K, To F et al (2023) Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/kead404","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"7019_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang X, Ye S (2019) Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med 381(3):291\u2013293. https:\/\/doi.org\/10.1056\/NEJMc1900045","journal-title":"N Engl J Med"},{"issue":"12","key":"7019_CR31","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","volume":"57","author":"K Kurasawa","year":"2018","unstructured":"Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T et al (2018) Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford) 57(12):2114\u20132119. https:\/\/doi.org\/10.1093\/rheumatology\/key188","journal-title":"Rheumatology (Oxford)"},{"key":"7019_CR32","doi-asserted-by":"publisher","unstructured":"Zhang J, Sun L, Shi X, Li S, Liu C, Li X, Lu M, Deng J, Tan X, Guan W, Li G, Wen X, Liu P, Li C (2023) Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China.\u00a0Arthritis Res Ther\u00a025(1):204. https:\/\/doi.org\/10.1186\/s13075-023-03170-z","DOI":"10.1186\/s13075-023-03170-z"},{"issue":"8","key":"7019_CR33","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","volume":"152","author":"DJ Kurtzman","year":"2016","unstructured":"Kurtzman DJ, Wright NA, Lin J, Femia AN, Merola JF, Patel M, Vleugels RA (2016) Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol 152(8):944\u2013945. https:\/\/doi.org\/10.1001\/jamadermatol.2016.0866","journal-title":"JAMA Dermatol"},{"key":"7019_CR34","doi-asserted-by":"publisher","unstructured":"Navarro-Navarro I, Jim\u00e9nez-Gallo D, Rodr\u00edguez-Mateos ME, Rodr\u00edguez-Hern\u00e1ndez C, Linares-Barrios M (2021) Treatment of refractory anti-NXP2 and anti-TIF1\u03b3 dermatomyositis with tofacitinib. J Dtsch Dermatol Ges 19(3):443\u2013447. https:\/\/doi.org\/10.1111\/ddg.14276","DOI":"10.1111\/ddg.14276"},{"issue":"4","key":"7019_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.08.009","volume":"46","author":"JJ Paik","year":"2017","unstructured":"Paik JJ, Christopher-Stine L (2017) A case of refractory dermatomyositis responsive to tofacitinib. Semin Arthritis Rheum 46(4):e19. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.08.009","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"7019_CR36","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1080\/08998280.2020.1821589","volume":"34","author":"P Williams","year":"2020","unstructured":"Williams P, McKinney B (2020) Refractory dermatomyositis-systemic lupus erythematosus overlap syndrome and response to tofacitinib. Proc (Baylor University Medical Center) 34(1):116\u2013117. https:\/\/doi.org\/10.1080\/08998280.2020.1821589","journal-title":"Proc (Baylor University Medical Center)"},{"key":"7019_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","volume":"100","author":"S Wendel","year":"2019","unstructured":"Wendel S, Venhoff N, Frye BC, May AM, Agarwal P, Rizzi M, Voll RE, Thiel J (2019) Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - a report of two cases. J Autoimmun 100:131\u2013136. https:\/\/doi.org\/10.1016\/j.jaut.2019.03.003","journal-title":"J Autoimmun"},{"issue":"2","key":"7019_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.medcli.2021.03.022","volume":"158","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Weng R, Xia Y (2022) Refractory juvenile dermatomyositis: response to tofacitinib. Med Clin 158(2):95\u201396. https:\/\/doi.org\/10.1016\/j.medcli.2021.03.022","journal-title":"Med Clin"},{"issue":"11","key":"7019_CR39","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1093\/rheumatology\/keab421","volume":"60","author":"M Shneyderman","year":"2021","unstructured":"Shneyderman M, Ahlawat S, Christopher-Stine L, Paik JJ (2021) Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series. Rheumatology (Oxford) 60(11):e387\u2013e388. https:\/\/doi.org\/10.1093\/rheumatology\/keab421","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"7019_CR40","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3899\/jrheum.220367","volume":"49","author":"L Fan","year":"2022","unstructured":"Fan L, Lyu W, Liu H, Jiang H, Chen L, Liu Y, Zhuang Y, Huang M, Cao M, Cai H, Xiao Y, Dai J (2022) A retrospective analysis of outcome in melanoma differentiation-associated gene 5-related interstitial lung disease treated with tofacitinib or tacrolimus. J Rheumatol 49(12):1356\u20131364. https:\/\/doi.org\/10.3899\/jrheum.220367","journal-title":"J Rheumatol"},{"issue":"1","key":"7019_CR41","doi-asserted-by":"publisher","first-page":"e002795","DOI":"10.1136\/rmdopen-2022-002795","volume":"9","author":"T Ida","year":"2023","unstructured":"Ida T, Furuta S, Takayama A, Tamura J, Hayashi Y, Abe K, Kurihara S, Ishikawa J, Iwamoto T, Ikeda K, Suzuki K, Nakajima H (2023) Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD Open 9(1):e002795. https:\/\/doi.org\/10.1136\/rmdopen-2022-002795","journal-title":"RMD Open"},{"issue":"6","key":"7019_CR42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/RHU.0000000000002010","volume":"29","author":"S Li","year":"2023","unstructured":"Li S, Li S, Wang J, Zhang L, Duan J, Lu X, Zhang L, Wang G (2023) Efficacy and safety of tofacitinib in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. J Clin Rheumatol Pract Rep Rheum Musculoskeletal Dis 29(6):281\u2013284. https:\/\/doi.org\/10.1097\/RHU.0000000000002010","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskeletal Dis"},{"issue":"7","key":"7019_CR43","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s10067-023-06567-y","volume":"42","author":"Y Wang","year":"2023","unstructured":"Wang Y, Luo J, Lv X, Li Y, An Q, Mo L, Hu N, Zhang J, Wang J, Tian J, Pu D, Hao Z, He L (2023) Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis. Clin Rheumatol 42(7):1847\u20131853. https:\/\/doi.org\/10.1007\/s10067-023-06567-y","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07019-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07019-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07019-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T04:08:11Z","timestamp":1718683691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07019-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["7019"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07019-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from respective ethics committees: Institutional Ethics Committee, St. John\u2019s Medical College & Hospital. IEC Ref No. IEC\/1\/1054\/2023 dated 10\/September\/2023.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}